Australia's Mayne Pharma agrees to $25 million settlement for not disclosing US price-fixing allegations

By Saloni Sinha ( July 9, 2024, 06:15 GMT | Insight) -- South Australia-based pharmaceutical company Mayne Pharma has agreed to pay A$38 million ($25 million) to settle an Australian shareholder class action over the company's failure to disclose alleged anticompetitive conduct in the United States. In a statement to the Australian Securities Exchange this week, Mayne Pharma said the anticompetitive conduct in the United States was previously investigated by the US Department of Justice and the Office of the Attorney General in Connecticut. South Australia-based pharmaceutical company Mayne Pharma has agreed to pay A$38 million ($25 million) to settle an Australian shareholder class action lawsuit over the company's failure to disclose alleged anticompetitive conduct in the United States....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

Know what others in the room don’t, with features including:

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Australia's Mayne Pharma agrees to $25 million settlement for not disclosing US price-fixing allegations

Prepare for tomorrow’s regulatory change, today

Related Sections